Novo Nordisk Q4 Preview: Rybelsus’s Launch Key Focus
Analysts Expect Strong Q4 GLP-1 Volumes Offset By US Pricing Pressures
Ozempic's continued good growth and the ongoing roll out of oral Rybelsus should revitalize growth and expand Novo's reach in the diabetes market this year.
